# A Study Investigating the Efficacy and Safety of Ociperlimab and Tislelizumab and BAT1706 Combinations in Patients With Advanced HCC

> **NCT04948697** · PHASE2 · COMPLETED · sponsor: **BeiGene** · enrollment: 94 (actual)

## Conditions studied

- Advanced Hepatocellular Carcinoma

## Interventions

- **DRUG:** Ociperlimab
- **DRUG:** Tislelizumab
- **DRUG:** BAT1706

## Key facts

- **NCT ID:** NCT04948697
- **Lead sponsor:** BeiGene
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-08-20
- **Primary completion:** 2024-02-01
- **Final completion:** 2024-02-01
- **Target enrollment:** 94 (ACTUAL)
- **Last updated:** 2025-02-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04948697

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04948697, "A Study Investigating the Efficacy and Safety of Ociperlimab and Tislelizumab and BAT1706 Combinations in Patients With Advanced HCC". Retrieved via MORVS 2026-11-02 from https://api.morvs.ai/clinical/NCT04948697. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*